Press release
Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
Discover the latest drugs and treatment options in the Stargardt Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Stargardt Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Stargardt Disease Pipeline Report
* In August 2024:- Belite Bio Inc.- A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease.
* DelveInsight's Stargardt Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
* The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Promising Stargardt Disease Therapies such as OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
Stay ahead with the most recent pipeline outlook for Stargardt Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Stargardt Disease Treatment Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt Disease Emerging Drugs Profile
* Tinlarebant: Belite Bio
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Stargardt disease.
* KIO-301: Kiora Pharmaceuticals
KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of stargardt disease.
* OCU410: Ocugen
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of stargardt disease.
Explore groundbreaking therapies and clinical trials in the Stargardt Disease Pipeline. Access DelveInsight's detailed report now! @ New Stargardt Disease Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Stargardt Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Stargardt Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Stargardt Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Stargardt Disease Pipeline Report
* Coverage- Global
* Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Stargardt Disease Therapies- OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
* Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Stargardt Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Stargardt Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Stargardt Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Stargardt disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tinlarebant: Belite Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KIO-301: Kiora Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* OCU410: Ocugen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Stargardt disease Key Companies
* Stargardt disease Key Products
* Stargardt disease -Unmet Needs
* Stargardt disease -Market Drivers and Barriers
* Stargardt disease -Future Perspectives and Conclusion
* Stargardt disease Analyst Views
* Stargardt disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stargardt-disease-clinical-trials-pipeline-insights-treatment-drugs-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 here
News-ID: 3661656 • Views: …
More Releases from ABNewswire
How Cuppari Coffee Delivers Luxury-Tier Coffee Without the Luxury-Tier Price Tag …
Cuppari Coffee LLC is proving that premium small-batch coffee does not have to come with premium hidden costs. With free shipping on every U.S. order regardless of size, subscribe-and-save discounts, and a roast-to-order freshness guarantee, the company has built a model designed for the value-conscious coffee lover.
The specialty coffee market has grown rapidly over the past decade, but so have the costs that often accompany it. Between premium pricing, shipping…
United Water Restoration Group of Tampa Expands Water Restoration Company Servic …
United Water Restoration Group of Tampa provides 24/7 certified water restoration company services and water damage repair for residential and commercial properties across the Tampa Bay area.
Property damage from water intrusion, flooding, and storm-related incidents continues to affect homeowners and businesses across the Tampa Bay area. United Water Restoration Group of Tampa is addressing that growing need by providing certified, around-the-clock water restoration company services designed to minimize structural damage,…
Stand Out from the Crowd: 1228Teez Delivers One-of-a-Kind Graphic Tees Designed …
Woman-owned apparel brand 1228Teez is on a mission to help customers express themselves through unique, high-quality graphic tees that combine humor, originality, and inclusive sizing. The brand's growing collection offers designs that cannot be found through mainstream retailers.
The graphic tee has long been one of the most democratic pieces in fashion. It requires no styling expertise, works in nearly any casual setting, and offers a blank canvas for personal expression.…
Missed Calls Mean Lost Bookings as TransportBPO Enters the Market With Round-the …
With dispatcher shortages intensifying and customer patience shrinking, TransportBPO has launched a dedicated outsourcing service that gives ground transportation operators in four countries access to 24/7 trained dispatch and call coverage. The company targets the growing gap between what small and mid-size fleets can afford in-house and what modern passengers demand.
The economics of running a small or mid-size ground transportation business have shifted dramatically in recent years. Fuel costs fluctuate,…
More Releases for Stargardt
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Market was valued at USD 120-150 million in 2024
Market Overview
The Stargardt Disease market is expanding steadily as advancements in retinal imaging, genetic testing, and gene-therapy research accelerate therapeutic development. Stargardt Disease, the most common form of inherited juvenile macular degeneration, is caused primarily by mutations in the ABCA4 gene and leads to progressive central vision loss.
The global market for Stargardt Disease diagnosis, management, and emerging therapeutics was valued at USD 120-150 million in 2024. With increasing clinical-trial activity…
Stargardt Disease Market to Witness Promising Upswing by 2034, DelveInsight Fore …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Market Growth to Accelerate in Forecast Period (2024-2034) | e …
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Stargardt Disease Market with DelveInsight's In-Depth Report @ Stargardt Disease Market Size- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Stargardt Disease Market…
Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approva …
DelveInsight's, "Stargardt Disease Pipeline Insight 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Stargardt Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Global Juvenile Degeneration (Stargardt Disease) Market Forecast to 2025
Juvenile Degeneration (Stargardt Disease) Market report describes the thorough and collective examination of the Juvenile Degeneration (Stargardt Disease) industry during the past, present and conjecture periods. All the business verticals like driving market situation, regional Juvenile Degeneration (Stargardt Disease) nearness, and improvement openings are clarified. Top players of the Juvenile Degeneration (Stargardt Disease) industry, their business strategies, and growth opportunities are covered in this report. A report is incomplete without…
